Not Yet Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - CA052-1000
Atualizado: 26 junho, 2026 | ClinicalTrials.gov
Fase
Gênero(s)
Faixa etária
Localização(ões)
Not Yet Recruiting
Inclusion Criteria - Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition. - Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease. - Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site. - Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. - Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria - Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated. - Participants must not have prior treatment with immuno-oncology therapies. - Participants must not have untreated central nervous system (CNS) metastases. - Other protocol-defined Inclusion/Exclusion criteria apply.
É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas
